- Home
- SENEA vs VERV Comparison
SENEA vs VERV Comparison
Compare SENEA & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SENEA
- VERV
- Stock Information
- Founded
- SENEA 1949
- VERV 2018
- Country
- SENEA United States
- VERV United States
- Employees
- SENEA N/A
- VERV N/A
- Industry
- SENEA Packaged Foods
- VERV Medicinal Chemicals and Botanical Products
- Sector
- SENEA Consumer Staples
- VERV Health Care
- Exchange
- SENEA Nasdaq
- VERV Nasdaq
- Market Cap
- SENEA 557.7M
- VERV 475.0M
- IPO Year
- SENEA N/A
- VERV 2021
- Fundamental
- Price
- SENEA $80.49
- VERV $7.28
- Analyst Decision
- SENEA
- VERV Strong Buy
- Analyst Count
- SENEA 0
- VERV 4
- Target Price
- SENEA N/A
- VERV $25.75
- AVG Volume (30 Days)
- SENEA 13.7K
- VERV 1.3M
- Earning Date
- SENEA 02-06-2025
- VERV 02-28-2025
- Dividend Yield
- SENEA N/A
- VERV N/A
- EPS Growth
- SENEA 25.61
- VERV N/A
- EPS
- SENEA 5.45
- VERV N/A
- Revenue
- SENEA $1,541,031,000.00
- VERV $24,396,000.00
- Revenue This Year
- SENEA N/A
- VERV $106.46
- Revenue Next Year
- SENEA N/A
- VERV N/A
- P/E Ratio
- SENEA $14.77
- VERV N/A
- Revenue Growth
- SENEA 4.01
- VERV 219.91
- 52 Week Low
- SENEA $46.56
- VERV $4.31
- 52 Week High
- SENEA $81.45
- VERV $19.34
- Technical
- Relative Strength Index (RSI)
- SENEA 65.40
- VERV 47.08
- Support Level
- SENEA $77.08
- VERV $7.44
- Resistance Level
- SENEA $81.45
- VERV $9.31
- Average True Range (ATR)
- SENEA 2.00
- VERV 0.67
- MACD
- SENEA 0.54
- VERV -0.12
- Stochastic Oscillator
- SENEA 90.83
- VERV 14.01
About SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.